J&J vaccine approved for emergency use in Canada
Ten million doses expected by end of Q3
Johnson & Johnson, who has been making production headlines in the US, recently revealed that Health Canada has granted an interim order (IO) authorization for its single-shot Covid-19 vaccine, developed by J&J's Janssen Pharmaceutical Companies unit, to prevent Covid-19 in people 18 years of age and older.
This decision was based on scientific evidence, including data from the Phase III ENSEMBLE study that demonstrated the vaccine was 85% effective in preventing severe disease, and exhibited protection against Covid-19 related hospitalization and death, beginning 28 days after vaccination.
J&J envisions fulfilling the 10 million doses included in the advance purchase agreement with the government of Canada by the end of Q3.
Antares Vision Group, Siempharma Strike Up Pharma Labeling Equipment Collaboration
May 8th 2025The track-and-trace systems provider expands its life sciences portfolio by integrating the high-speed, adaptable ETF-300 precision labeler through a partnership that brings Industry 4.0-ready capabilities, advanced printing tech, and enhanced data security to pharmaceutical packaging.
